Harmony Biosciences Holdings Inc represents a commitment to improving the lives of patients with rare neurological disorders. The company's corporate philosophy centers around providing innovative treatment solutions and fostering collaboration within the healthcare community. By prioritizing patient needs, Harmony Biosciences focuses on developing and commercializing therapies that address unmet medical needs. With a strong emphasis on research and development, the company aims to bring transformative therapies to individuals with sleep and central nervous system disorders. Harmony Biosciences Holdings Inc strives to enhance patient outcomes by delivering novel treatment options and advancing the understanding of these conditions.

Harmony Biosciences Holdings Inc is primarily present in the United States.

Harmony Biosciences Holdings Inc has achieved several significant milestones. The company successfully launched its flagship product, Wakix® (pitolisant), a medication for the treatment of narcolepsy, in the United States. Harmony Biosciences Holdings Inc also received approval from the U.S. Food and Drug Administration (FDA) for the expanded use of Wakix® in treating excessive daytime sleepiness associated with both obstructive sleep apnea and narcolepsy. Additionally, the company secured partnerships and collaborations to enhance research and development efforts. Harmony Biosciences Holdings Inc continues to strive for advancements in treating sleep-wake disorders, making notable strides in improving the lives of patients worldwide.

Harmony Biosciences Holdings Inc is a pharmaceutical company focused on developing and commercializing innovative therapies to address sleep and central nervous system disorders. Founded in 2017, Harmony Biosciences aims to improve the lives of patients with unmet medical needs through the advancement of science and compassionate care. The company's primary product, Pitolisant, is the first and only medication approved by the FDA for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Harmony Biosciences is committed to providing effective solutions for patients suffering from sleep-related disorders and has rapidly gained recognition in the biopharmaceutical industry.

The main competitors of Harmony Biosciences Holdings Inc in the market are pharmaceutical companies such as Jazz Pharmaceuticals, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. They operate in the same industry and offer similar products and services. These competitors also focus on developing and commercializing therapies for sleep and central nervous system disorders, just like Harmony Biosciences Holdings Inc. It is essential for Harmony Biosciences to constantly innovate and differentiate itself from these competitors to maintain a strong position in the market.

Harmony Biosciences Holdings Inc is primarily active in the pharmaceutical industry.

The business model of Harmony Biosciences Holdings Inc revolves around discovering, developing, and delivering innovative therapies for patients with sleep and central nervous system disorders. With a focus on improving the lives of individuals living with narcolepsy, the company specializes in developing and commercializing treatment options that address the unmet medical needs of this patient population. By leveraging scientific expertise and strategic partnerships, Harmony Biosciences aims to provide effective solutions, fostering better sleep health and overall well-being for those affected by sleep-related disorders. Harmony Biosciences Holdings Inc is committed to driving positive patient outcomes through its dedicated efforts in the field of sleep medicine.

Harmony Biosciences Holdings hissesinin F/K oranı 18,28.

Harmony Biosciences Holdings KUV 3,27 dir.

Harmony Biosciences Holdings için AlleAktien Kalite Skoru 6/10'dur.

beklenen Harmony Biosciences Holdings cirosu 723,84 Milyon. USD dir.

beklenen Harmony Biosciences Holdings karı 129,60 Milyon. USD olarak gerçekleşmiştir.

Harmony Biosciences Holdings Inc is a leading provider of innovative therapies and products for the treatment of sleep disorders and other neurological diseases. The company is based in Plymouth Meeting, Pennsylvania, and has been operating since 2016. The business model of Harmony Biosciences is focused on providing effective and long-lasting relief of symptoms for patients with sleep disorders and their consequences. To this end, the company has developed a wide range of products that can be prescribed by doctors and clinics for the treatment of sleep disorders. These include medications such as Pitolisant, used for the treatment of narcolepsy, or Wakix, used for the treatment of excessive daytime sleepiness (EDS) in narcolepsy. Harmony Biosciences specializes not only in the development of medications and therapies, but also offers comprehensive support for the treatment of patients with sleep disorders. A wide network of medical professionals, including doctors, neurologists, and sleep specialists, is available to assist patients in the prevention and treatment of sleep disorders. The company has also invested in the field of medical devices to develop innovative products such as wearable devices for monitoring sleep patterns. These devices capture measurements such as breathing rate, heart rate, movement patterns, and snoring to help assess sleep quality and improve the treatment of sleep disorders. In addition to developing and marketing medications and medical devices, Harmony Biosciences specializes in collaborating with other companies. The company has already formed numerous partnerships with other companies in the field of sleep medicine to jointly discover innovative solutions for the treatment of sleep disorders. In the future, the company plans to further expand its business and drive the development of new products. This includes further improving its medications and medical devices, as well as expanding its network of medical professionals and partners. Overall, Harmony Biosciences Holdings Inc's business model has the potential to remain a key player in the sleep medicine market and make a significant contribution to improving the treatment of sleep disorders.

Harmony Biosciences Holdings, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Harmony Biosciences Holdings için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Harmony Biosciences Holdings şirketinin ISIN kodu US4131971040’dir.

Harmony Biosciences Holdings 'nin WKN'si A2QBSF 'dir.

Harmony Biosciences Holdings için Ticker HRMY’dir.

Son 12 ay içerisinde Harmony Biosciences Holdings, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Harmony Biosciences Holdings, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Harmony Biosciences Holdings şirketinin mevcut temettü verimi .

Harmony Biosciences Holdings dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Harmony Biosciences Holdings, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Harmony Biosciences Holdings, 'Sağlık' sektörüne atanmıştır.

Son Harmony Biosciences Holdings tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 02.10.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 02.10.2024 olarak gerçekleşti.

2023 yılında Harmony Biosciences Holdings tarafından 0 USD olarak temettüler dağıtıldı.

Harmony Biosciences Holdings hisselerinin temettüleri USD olarak dağıtılır.